- Trials with a EudraCT protocol (870)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
870 result(s) found for: Reproductive health.
Displaying page 1 of 44.
EudraCT Number: 2020-004112-10 | Sponsor Protocol Number: PROTECTA | Start Date*: 2020-12-16 |
Sponsor Name:Ghent University Hospital | ||
Full Title: Randomized controlled trial comparing micronized progesterone (Amelgen ®) 400 mg BID versus 400 mg TID for luteal support in artificial vitrified/warmed single blastocyst transfer cycles with low p... | ||
Medical condition: Patients who undergo artificial vitrified/warmed single blastocyst transfer cycles with low progesterone (defined as <10mcg/l) on day of embryo transfer. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002135-30 | Sponsor Protocol Number: NCT04379973 | Start Date*: 2021-04-28 |
Sponsor Name:Antwerp University Hospital (UZA) | ||
Full Title: Live birth after additional tubal flushing with oil-based contrast versus no additional flushing: a randomised, multicentre, parallel group pragmatic trial in infertile women with at least one pate... | ||
Medical condition: Infertility defined as lack of conception despite 12 months of unprotected intercourse, or three cycles of donor insemination without pregnancy or three ovulatory ovulation induction cycles without... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001736-35 | Sponsor Protocol Number: 15-OBE2109-001 | Start Date*: 2016-08-29 | |||||||||||||||||||||
Sponsor Name:ObsEva SA | |||||||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, phase 2b dose-ranging study to assess the efficacy and safety of OBE2109 in subjects with endometriosis associated pain. | |||||||||||||||||||||||
Medical condition: Treatment of Endometriosis-Associated Pain | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: PL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-004492-12 | Sponsor Protocol Number: SCY-078-306 | Start Date*: 2019-06-05 | |||||||||||
Sponsor Name:SCYNEXIS, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects with Acute Vulvovaginal Candid... | |||||||||||||
Medical condition: Acute Vulvovaginal Candidiasis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000134-34 | Sponsor Protocol Number: TEAM(B115UCS2019) | Start Date*: 2021-05-24 | |||||||||||
Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | |||||||||||||
Full Title: Time restricted Eating And Metformin (TEAM) in invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS). A randomized, phase IIb, window of opportunity presurgical trial. | |||||||||||||
Medical condition: Luminal (ER+ve and/or PgR+ve >=1%) invasive breast cancer not candidate to neo - adjuvant chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000328-85 | Sponsor Protocol Number: FINNHT1 | Start Date*: 2017-05-18 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Helsinki University Hospital, Obstetrics and Gynecology | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Randomized comparative trial between abrupt and tapered mode of discontinuation of longterm hormone therapy: Impact on endothelial function, recurrence of vasomotor symptoms and quality of life | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: We will assess the effects of hormone therapy termination on endothelial function using biophysical (flow-mediated dilation, peripheral artery tonometry) and biochemical markers. We will compare th... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FI (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003810-42 | Sponsor Protocol Number: Version2.0;18/12/2013 | Start Date*: 2016-06-24 | ||||||||||||||||
Sponsor Name:University of Edinburgh (ACCORD) [...] | ||||||||||||||||||
Full Title: A pragmatic group sequential placebo controlled randomised trial to determine the effectiveness of Glyceryl trinitrate for retained placenta (GOT-IT Trial) | ||||||||||||||||||
Medical condition: Retained placenta | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001824-32 | Sponsor Protocol Number: 116174 | Start Date*: 2015-03-05 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in pa... | |||||||||||||
Medical condition: Diabetes mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) CZ (Completed) GB (Completed) SE (Completed) NL (Completed) HU (Completed) BE (Completed) DK (Completed) ES (Completed) BG (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002812-33 | Sponsor Protocol Number: 204824 | Start Date*: 2016-02-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Phase 2 Pilot, Multicenter, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GSK1070806 plus Standard of Care for the Prevention of Delayed Graft Function ... | |||||||||||||
Medical condition: Delayed Graft Function in Adult Subjects After Renal Transplantation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005117-72 | Sponsor Protocol Number: AG120-C-005 | Start Date*: 2017-04-24 | ||||||||||||||||
Sponsor Name:Agios Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation | ||||||||||||||||||
Medical condition: Nonresectable or Metastatic Cholangiocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003788-67 | Sponsor Protocol Number: FS1306 | Start Date*: 2014-01-29 | |||||||||||
Sponsor Name:Watson Laboratories, Inc. - A subsidiary of Actavis, Inc. | |||||||||||||
Full Title: A Randomised, Parallel Group, Assessor-Blind, Multicentre Study to Compare the Safety and Efficacy of Watson rhFSH with Follitropin Alfa (GONAL-f) in Stimulating Multiple Follicular Development in ... | |||||||||||||
Medical condition: Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer and... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016375-30 | Sponsor Protocol Number: MK-0462-086 | Start Date*: 2010-02-16 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura | |||||||||||||
Medical condition: Long term treatment of acute migraine, with or without aura, in children and adolescents, ages 12 to 17 years. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) FI (Completed) DE (Completed) BE (Completed) ES (Prematurely Ended) EE (Completed) LV (Prematurely Ended) SE (Completed) FR (Prematurely Ended) PL (Prematurely Ended) DK (Completed) NO (Completed) GB (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004266-25 | Sponsor Protocol Number: 16-OBE001-005 | Start Date*: 2017-02-24 | |||||||||||
Sponsor Name:ObsEva S.A. | |||||||||||||
Full Title: A phase 3, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of a single oral administration of nolasiban to improve pregnancy rates following IVF or ICSI in Day ... | |||||||||||||
Medical condition: Embryo implantation in women undergoing IVF or ICSI with Day 3 or Day 5 fresh embryo transfer cycles, in the context of Assisted Reproductive Technology (ART). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) DK (Completed) BE (Completed) HU (Completed) EE (Completed) ES (Completed) FI (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018421-19 | Sponsor Protocol Number: PASS | Start Date*: 2010-05-05 | ||||||||||||||||
Sponsor Name:AMC | ||||||||||||||||||
Full Title: Preventive Antibiotics in Stroke Study | ||||||||||||||||||
Medical condition: Stroke and stroke-associated infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002600-40 | Sponsor Protocol Number: SCY-078-304 | Start Date*: 2020-01-17 | |||||||||||
Sponsor Name:SCYNEXIS, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects with Recurrent Vulvova... | |||||||||||||
Medical condition: Recurrent Vulvovaginal Candidiasis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001232-11 | Sponsor Protocol Number: 200622 | Start Date*: 2016-11-16 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: Study 200622: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of mepolizumab in the treatment of adolescent and adult subjects with severe hypereosinophi... | |||||||||||||
Medical condition: severe hypereosinophilic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) DE (Completed) FR (Completed) BE (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016374-32 | Sponsor Protocol Number: MK-0462-082 | Start Date*: 2010-02-15 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adole... | |||||||||||||
Medical condition: Acute treatment of migraine, with or without aura, in children and adolescents, ages 6 to 17 years, who do not have a satisfactory response to prior treatment with nonsteroidal anti-inflammatory dr... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) FI (Completed) BE (Completed) ES (Completed) EE (Completed) LV (Completed) SE (Completed) FR (Completed) DK (Completed) GB (Completed) IT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002367-26 | Sponsor Protocol Number: CLI18001/Lita-003 | Start Date*: 2019-03-27 | |||||||||||
Sponsor Name:Litaphar Laboratorios | |||||||||||||
Full Title: A randomized, double-blind, three-arm, parallel-group, multicentre superiority study assessing the efficacy and safety of mifepristone (2.5 mg and 5 mg) vs. placebo for the treatment of endometrios... | |||||||||||||
Medical condition: endometriosis in reproductive-age | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000375-25 | Sponsor Protocol Number: BotA-KKDS2016 | Start Date*: 2016-04-19 |
Sponsor Name:Danderyds sjukhus AB | ||
Full Title: Double blind placebo-controlled RCT of the efficacy and safety of intramuscular injections of Botulinum Toxin A as a treatment for provoked vestibulodynia | ||
Medical condition: Provoked vestibulodynia | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001618-27 | Sponsor Protocol Number: EMN14/54767414MMY3013 | Start Date*: 2017-05-19 | |||||||||||
Sponsor Name:Stichting European Myeloma Network (EMN) | |||||||||||||
Full Title: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy Wi... | |||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) ES (Ongoing) BE (Completed) DE (Completed) CZ (Completed) DK (Completed) FR (Completed) NL (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
